Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT® (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
Recruiting
21 years - 100 years
All
Phase
2
1 Location
Brief description of study
Alternating phone and in-clinic visits for medical management (MM), laboratory tests, and physical exams, to assess drug compliance, to complete additional questionnaires, and to provide counseling (via “Take Control” videos) over 29 weeks.
Detailed description of study
The primary objective of the study is to compare the efficacy of HORIZANT (gabapentin enacarbil) Extended-Release Tablets 600 mg twice daily (BID) with matched placebo on the primary alcohol consumption outcome endpoint, percentage of subjects with no heavy drinking days (PSNHDD) during the last 4 weeks of treatment, among patients with Alcohol Use Disorder (AUD).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alcoholic Intoxication, Alcoholism, Addictive Behavior, medication, Alcohol Use Disorder, Alcohol-Related Disorders
-
Age: 21 years - 100 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 821946
Find a site
,
Your Information has been sent successfully.
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Message For Non Enrolling By Invitation Trial
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or